- |||||||||| ALLO-647 / Allogene Therap, ALLO-605 / Allogene Therap
Enrollment closed, Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 14, 2023
P1/2, N=136, Active, not recruiting,
Trial completion date: Jan 2027 --> Jul 2025 | Trial primary completion date: Jan 2024 --> Jul 2025 | Recruiting --> Active, not recruiting
- |||||||||| ALLO-715 / Allogene Therap, Actemra IV (tocilizumab) / Roche, JW Pharma
Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma (GWCC - Sidney Marcus Auditorium, Level 4) - Nov 5, 2021 - Abstract #ASH2021ASH_2114;
P1
Several LD regimens are being evaluated: FCA39; FCA60; FCA90; and CA39; with fludarabine [F] 90 mg/m 2 , cyclophosphamide [C] 900 mg/m 2 , and ALLO-647 [A] 39, 60, or 90 mg divided over 3 days...CRS was treated with tocilizumab (21.3%) and corticosteroids (12.8%)...A study using the next generation anti-BCMA CAR (ALLO-605) which supplies cytokine signaling to the CAR bearing cells is ongoing (IGNITE). The current UNIVERSAL trial continues to enroll, including a cohort with consolidation, and updated data will be presented at the meeting.
- |||||||||| ALLO-647 / Allogene Therap, ALLO-605 / Allogene Therap
Enrollment closed, CAR T-Cell Therapy: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 13, 2021
P1/2, N=136, Active, not recruiting,
The current UNIVERSAL trial continues to enroll, including a cohort with consolidation, and updated data will be presented at the meeting. Recruiting --> Active, not recruiting
- |||||||||| ALLO-605 / Allogene Therap, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Preclinical Evaluation of ALLO-605, an Allogeneic BCMA Turbocar TTM Cell Therapy for the Treatment of Multiple Myeloma (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_4056;
In addition, we confirmed rapid inhibition of BCMA TurboCAR T™ cells by the protein tyrosine kinase inhibitor dasatinib, which has been shown to interfere with LCK activity. The prolonged persistence and antitumor responses seen in preclinical models along with a favorable safety profile of BCMA TurboCAR™ T cells support clinical investigation of ALLO-605 in relapsed or refractory multiple myeloma.
|
